1140 Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas

1140 Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas

Bibliographic Details
Main Authors:	Shuai Chen, Tianhong Li, Dennis J Montoya, Siqi Long, Kyra A Toomey, Varun Viswanath, Michael Babich
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer
by: Weijie Ma, et al.
Published: (2023-02-01)

Topology and adenocarcinoma cell localization dataset on the labyrinthin diapeutic biomarker
by: Ankit Sharma, et al.
Published: (2023-07-01)

40 Novel biomarker assays for detecting labyrinthin-positive adenocarcinomas for a phase I/II trial of peptide vaccine LabVax 3(22)-23 alone or in combination with pembrolizumab
by: Tianhong Li, et al.
Published: (2023-11-01)

632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas
by: Shuai Chen, et al.
Published: (2023-11-01)

Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma
by: Hoi-Hin Kwok, et al.
Published: (2023-05-01)

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
by: Natalie I. Vokes, et al.
Published: (2023-03-01)

Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer
by: Yosuke Miura, et al.
Published: (2018-07-01)

Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma
by: Linh Dieu Vuong, et al.
Published: (2023-08-01)

The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells
by: Giovanna Butera, et al.
Published: (2020-06-01)

Overcoming MET-mediated resistance in oncogene-driven NSCLC
by: Nadine Reischmann, et al.
Published: (2023-07-01)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
by: Marina Salmón, et al.
Published: (2023-04-01)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
by: Antonella Catalano, et al.
Published: (2021-04-01)

Identification and Analysis of SND1 as an Oncogene and Prognostic Biomarker  for Lung Adenocarcinoma
by: Ruihao ZHANG, et al.
Published: (2024-01-01)

Oncogene and cancer /
by: Dennis, Eden, editor
Published: (2015)

Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis
by: Yin, C, et al.
Published: (2019)

The Chemokine System in Oncogenic Pathways Driven by Viruses: Perspectives for Cancer Immunotherapy
by: Géraldine Schlecht-Louf, et al.
Published: (2022-02-01)

Oncogenic EFNA4 Amplification Promotes Lung Adenocarcinoma Lymph Node Metastasis
by: Xiangyu Zhao, et al.
Published: (2022-08-01)

139 Identifying neoantigens in lung adenocarcinoma patients
by: Elizabeth Gensterblum-Miller, et al.
Published: (2023-11-01)

Niche heterogeneity impacts evolution of myeloproliferative neoplasms driven by the same oncogenic pathway
by: Korn, C, et al.
Published: (2018)

Editorial: Recent advances in diagnosis, prognosis, and therapy of oncogenic virus-driven tumors
by: Mauro Tognon, et al.
Published: (2024-04-01)

Oncogenes /
by: 311669 Cooper, Geoffrey M.
Published: (1995)

Oncogenes.
by: C Manso
Published: (1986-08-01)

Oncogene and cancer : advanced topics /
by: Dennis, Eden, editor
Published: (2015)

Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis
by: Jiayan Chen, et al.
Published: (2024-02-01)

NRF2 in Cancer: Cross-Talk with Oncogenic Pathways and Involvement in Gammaherpesvirus-Driven Carcinogenesis
by: Mara Cirone, et al.
Published: (2022-12-01)

Oncogenic pathway driven by p85β: upstream signals to activate p110
by: Ling Rao, et al.
Published: (2020-09-01)

Advances in lung adenocarcinoma: A novel perspective on prognoses and immune responses of CENPO as an oncogenic superenhancer
by: Tongdong Shi, et al.
Published: (2023-08-01)

FAM83H‐AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma
by: Siwei Wang, et al.
Published: (2021-02-01)

The Oncogenic Role of KLF7 in Colon Adenocarcinoma and Therapeutic Perspectives
by: Zhenjia Li, et al.
Published: (2023-01-01)

Labyrinthine patterns transitions
by: S. Echeverría-Alar, et al.
Published: (2020-12-01)

Oncogene proteins.
by: Malloy, Artur H., et al.
Published: (c200)

Oncogene proteins.
by: Murphy, Peter B., et al.
Published: (c200)

Oncogenic β-catenin-driven liver cancer is susceptible to methotrexate-mediated disruption of nucleotide synthesis
by: Fangming Liu, et al.
Published: (2024-01-01)

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia
by: Nuria Tubío-Santamaría, et al.
Published: (2023-12-01)

Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma
by: Yiping Tian, et al.
Published: (2022-02-01)

Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
by: Huanhuan Hu, et al.
Published: (2023-01-01)

AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma
by: Dengxia Fan, et al.
Published: (2023-10-01)

Pan-cancer analysis of LINC02535 as a potential biomarker and its oncogenic role in lung adenocarcinoma
by: Shuang Dai, et al.
Published: (2022-12-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells
by: Geoffrey Brown
Published: (2021-09-01)